Automated capillary Western dot blot method for the identity of a 15-valent pneumococcal conjugate vaccine

被引:23
|
作者
Hamm, Melissa [1 ]
Ha, Sha [1 ]
Rustandi, Richard R. [1 ]
机构
[1] Merck Res Labs, Vaccine Analyt Dev, West Point, PA 19486 USA
关键词
Pneumococcal conjugate vaccine; Dot blot; Capillary Western; Simple Western; CRM197; Polysaccharide; POLYSACCHARIDES; QUANTITATION; SYSTEM;
D O I
10.1016/j.ab.2015.03.021
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Simple Western is a new technology that allows for the separation, blotting, and detection of proteins similar to a traditional Western except in a capillary format. Traditionally, identity assays for biological products are performed using either an enzyme-linked immunosorbent assay (ELISA) or a manual dot blot Western. Both techniques are usually very tedious, labor-intensive, and complicated for multivalent vaccines, and they can be difficult to transfer to other laboratories. An advantage this capillary Western technique has over the traditional manual dot blot Western method is the speed and the automation of electrophoresis separation, blotting, and detection steps performed in 96 capillaries. This article describes details of the development of an automated identity assay for a 15-valent pneumococcal conjugate vaccine, PCV15-CRM197, using capillary Western technology. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:33 / 39
页数:7
相关论文
共 50 条
  • [1] Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine
    Sobanjo-ter Meulen, Ajoke
    Vesikari, Timo
    Malacaman, Edgardo A.
    Shapiro, Steven A.
    Dallas, Michael J.
    Hoover, Patricia A.
    McFetridge, Richard
    Stek, Jon E.
    Marchese, Rocio D.
    Hartzel, Jonathan
    Watson, Wendy J.
    Musey, Luwy K.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (02) : 186 - 194
  • [2] Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults
    McFetridge, Richard
    Meulen, Ajoke Sobanjo-ter
    Folkerth, Steven D.
    Hoekstra, John A.
    Dallas, Michael
    Hoover, Patricia A.
    Marchese, Rocio D.
    Zacholski, Donna M.
    Watson, Wendy J.
    Stek, Jon E.
    Hartzel, Jonathan S.
    Musey, Luwy K.
    VACCINE, 2015, 33 (24) : 2793 - 2799
  • [3] Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine
    Whang, Yoon Hee
    Kim, Soo Kyung
    Yoon, Hyeseon
    Choi, Seuk Keun
    Baik, Yeong Ok
    Lee, Chankyu
    Lee, Inhwan
    PLOS ONE, 2020, 15 (12):
  • [4] Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
    Pan, Lu-Lu
    Gao, Zhao
    Zhou, Wei-Wei
    Li, Min-Jie
    Fang, Wen-Jian
    Ji, Wen-Juan
    Zhao, Ying
    Du, Lin
    Zhao, Yu-Liang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [5] Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
    Gourzoulidis, George
    Barmpouni, Myrto
    Kossyvaki, Vasiliki
    Vietri, Jeffrey
    Tzanetakos, Charalampos
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [6] COST-EFFECTIVENESS OF THE 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE VS 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR A./ULTS IN ARGENTINA
    Mac Mullen, M.
    Carballo, C.
    Seyahian, E.
    VALUE IN HEALTH, 2022, 25 (12) : S132 - S132
  • [7] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
    Greenberg, David
    Hoover, Patricia A.
    Vesikari, Timo
    Peltier, Christopher
    Hurley, David C.
    McFetridge, Richard D.
    Dallas, Michael
    Hartzel, Jonathan
    Marchese, Rocio D.
    Coller, Beth-Ann G.
    Stek, Jon E.
    Abeygunawardana, Chitrananda
    Winters, Michael A.
    MacNair, John E.
    Pujar, Narahari S.
    Musey, Luwy
    VACCINE, 2018, 36 (45) : 6883 - 6891
  • [8] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥50 years of age
    Ermlich, Susan J.
    Andrews, Charles P.
    Folkerth, Steven
    Rupp, Richard
    Greenberg, David
    McFetridge, Richard D.
    Hartzel, Jonathan
    Marchese, Rocio D.
    Stek, Jon E.
    Abeygunawardana, Chitrananda
    Musey, Luwy K.
    VACCINE, 2018, 36 (45) : 6875 - 6882
  • [9] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Peterson, James T.
    Stacey, Helen L.
    MacNair, John E.
    Li, Jianing
    Hartzel, Jonathan S.
    Sterling, Tina M.
    Benner, Patrice
    Tamms, Gretchen M.
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 540 - 548
  • [10] Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity
    Lee, Chankyu
    Choi, Seuk Keun
    Kim, Rock Ki
    Kim, Heeyoun
    Whang, Yoon Hee
    Pharm, Huyen
    Cheon, Hyunwoo
    Yoon, Do-Young
    Kim, Chan Wha
    Baik, Yeong Ok
    Park, Sung Soo
    Lee, Inhwan
    BIOLOGICALS, 2019, 61 : 32 - 37